We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

99 hedge funds and large institutions have $732M invested in ArriVent BioPharma in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

36% more capital invested

Capital invested by funds: $539M → $732M (+$193M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

19% more funds holding

Funds holding: 83 → 99 (+16)

12.82% more ownership

Funds ownership: 85.46% → 98.29% (+13%)

17% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 30

Holders
99
Holders Change
+16
Holders Change %
+19.28%
% of All Funds
1.3%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.08%
New
26
Increased
25
Reduced
30
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IAM
Infinitum Asset Management
Florida
+$28.1M
2
SCM
Suvretta Capital Management
New York
+$22.3M
3
SL
Siren LLC
Connecticut
+$14.5M
4
F1I
Fund 1 Investments
Puerto Rico
+$11M
5
CLG
Cooperman Leon G
+$8.75M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.26M
2
UBS Group
UBS Group
Switzerland
-$2.4M
3
OCA
Octagon Capital Advisors
New York
-$2.35M
4
Two Sigma Investments
Two Sigma Investments
New York
-$765K
5
Marshall Wace
Marshall Wace
United Kingdom
-$663K
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
1
HHLR Advisors
Cayman Islands
$97.6M – – –
IAM
2
Infinitum Asset Management
Florida
$74.4M +$28.1M +1,352,685 +65%
SCM
3
Suvretta Capital Management
New York
$74.3M +$22.3M +1,075,292 +46%
O
4
OrbiMed
New York
$65.9M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$44.8M -$428K -20,590 -1%
OCA
6
Octagon Capital Advisors
New York
$42.4M -$2.35M -113,333 -6%
NHAS
7
Novo Holdings A/S
Denmark
$40.8M – – –
BlackRock
8
BlackRock
New York
$40M -$6.26M -301,412 -14%
SI
9
Sofinnova Investments
California
$36.9M – – –
GCGM
10
General Catalyst Group Management
Massachusetts
$32.5M – – –
Vanguard Group
11
Vanguard Group
Pennsylvania
$32.3M -$412K -19,818 -1%
State Street
12
State Street
Massachusetts
$16.1M -$560K -26,948 -4%
SL
13
Siren LLC
Connecticut
$15.2M +$14.5M +700,000 New
HH
14
HSG Holding
Hong Kong
$14.4M – – –
HLAM
15
Hidden Lake Asset Management
New York
$13.2M +$7.32M +352,480 +139%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$13M -$384K -18,505 -3%
F1I
17
Fund 1 Investments
Puerto Rico
$11.5M +$11M +528,395 New
CLG
18
Cooperman Leon G
$9.17M +$8.75M +421,278 New
Goldman Sachs
19
Goldman Sachs
New York
$7.38M +$5.45M +262,319 +341%
Northern Trust
20
Northern Trust
Illinois
$4.5M -$643K -30,946 -13%
Squarepoint
21
Squarepoint
New York
$4.45M +$3.86M +185,929 +1,009%
Charles Schwab
22
Charles Schwab
California
$4.1M -$172K -8,292 -4%
Millennium Management
23
Millennium Management
New York
$3.84M +$376K +18,111 +11%
WP
24
Woodline Partners
California
$3.2M +$11.3K +543 +0.4%
Barclays
25
Barclays
United Kingdom
$2.55M +$1.59M +76,629 +189%
1
2 3 4 5

AVBP Hedge Fund Activity: Q2 2025 in Review

99 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2025, worth a combined $732M — up 36% from $539M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AVBP positions and 9 closed out — a net gain of 17 holders — while 25 added to existing stakes and 30 trimmed.

The largest buyer was Infinitum Asset Management, adding an estimated $28.1M. The largest seller was BlackRock, cutting an estimated $6.26M.

  • 99 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2025, up from 83 in Q1 2025.
  • Funds reported $732M of ArriVent BioPharma stock for Q2 2025, up 36% quarter-over-quarter.
  • 26 funds opened new ArriVent BioPharma positions in Q2 2025 and 9 closed out, a net change of +17 holders.
  • The largest ArriVent BioPharma buyer in Q2 2025 was Infinitum Asset Management, an estimated $28.1M added.
  • The largest ArriVent BioPharma seller in Q2 2025 was BlackRock, an estimated $6.26M sold.

Based on aggregated 13F filings for Q2 2025.